The 2026 LiBBY trial does not support THC and CBD use for mild cognitive impairment. It tested agitation in late-stage dementia, and safety questions remain open for that frail group. Mild cognitive impairment, or MCI, means early memory or thinking changes with daily independence intact. LiBBY enrolled a different population: hospice-eligible dementia patients with agitation.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did LiBBY test?
- Why did safety questions arise?
- Why don't the results apply to MCI?
- What should people with MCI discuss with a doctor?
What did LiBBY test?
The Alzheimer's Association describes LiBBY as a 12-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 study in 120 hospice-eligible patients with dementia-related agitation, presented at AAIC London AAIC 2026 trial summary. Participants averaged about 80 years old. They received a novel oral oil with 2 mg THC plus 100 mg CBD twice daily or placebo, with home-based visits across 10 U.S.
sites. The combination reduced Cohen-Mansfield Agitation Inventory scores by 10.61 points versus 4.35 for placebo at week 2. The separation persisted through week 12. NeurologyLive reports global improvement of 83.9% versus 30.5% at week 2 and 87.2% versus 23.6% at week 12 NeurologyLive trial report.
Why did safety questions arise?
Overall adverse events were similar between groups, at 46.7% versus 42.4%. Serious events were higher with THC and CBD, at 23.3% versus 11.9%, driven by serious infections at 11.7% versus 1.7%.
Deaths were 13.1% versus 5.1%, with no specific pattern reported. The official LiBBY Study site states investigators judged none of the serious events related to study medication, while noting that safety remains unresolved pending larger peer-reviewed data official study results.
Why don't the results apply to MCI?
MCI preserves independence and does not meet dementia severity. Late-stage, hospice-eligible dementia involves full dependence, frailty, and different medical risks.
Dose and product also matter. The benefit applies only to the specific purified THC and CBD dose and delivery system used under supervision. Dispensary oils, edibles, gummies, and over-the-counter CBD differ in dose, purity, and absorption.
What should people with MCI discuss with a doctor?
Do not try cannabis products to slow memory decline or prevent dementia. No LiBBY finding supports that use, and balance problems, confusion, drug interactions, and infection risk weigh more with age. Bring a clear list to the visit: Ask about local brain-health programs, caregiver support, and scheduled follow-up testing to track change over time.
- current memory symptoms, sleep problems, anxiety, and medications
- falls, daytime sleepiness, driving concerns, and alcohol use
- interest in approved MCI care, counseling, exercise, hearing, sleep, and blood-pressure management
- questions about clinical trials designed specifically for MCI
You Might Also Like
- AAIC 2026 LiBBY THC-CBD Agitation Trial: What the Findings Mean for People With Mild Cognitive Impairment
- Dementia With Multiple Etiologies in the 2026 NIA Report: Study Design and Evidence Limits for People With Mild Cognitive Impairment
- Strengths-Based Dementia Care in the 2026 NIA Report: Questions Spouses and Partners Can Ask Local Care Programs
